250 related articles for article (PubMed ID: 33656739)
1. Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y
Rheumatol Ther; 2021 Mar; 8(1):425-442. PubMed ID: 33656739
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
[TBL] [Abstract][Full Text] [Related]
5. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Tanaka Y; Takeuchi T; Izutsu H; Kaneko Y; Kato D; Fukuda M; Rokuda M; Schultz NM
Arthritis Res Ther; 2021 Aug; 23(1):221. PubMed ID: 34429152
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
[TBL] [Abstract][Full Text] [Related]
7. Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Genovese MC; Greenwald MW; Gutierrez-Ureña SR; Cardiel MH; Poiley JE; Zubrzycka-Sienkiewicz A; Codding CE; Wang A; He W; Amos R; Vinueza R; Wang X; Garg JP; Kivitz AJ
Rheumatol Ther; 2019 Dec; 6(4):503-520. PubMed ID: 31410787
[TBL] [Abstract][Full Text] [Related]
8. A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Takeuchi T; Tanaka Y; Rokuda M; Izutsu H; Kaneko Y; Fukuda M; Kato D
Mod Rheumatol; 2021 May; 31(3):543-555. PubMed ID: 33050760
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2).
Tanaka Y; Takeuchi T; Morita Y; Kaneko Y; Terada W
Mod Rheumatol; 2023 Dec; ():. PubMed ID: 38103258
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of peficitinib in Asian patients with rheumatoid arthritis who had an inadequate response or intolerance to methotrexate: results of a multicenter, randomized, double-blind, placebo-controlled phase 3 study.
Yang Y; Li J; Liu J; Liu L; Wang Y; Hu J; Li Z; Gu J; Zhang X; Xiao Z; Zheng J; Liu L; Li Z; Wei JC
Lancet Reg Health West Pac; 2024 Jan; 42():100925. PubMed ID: 38357391
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Tanaka Y; Takeuchi T; Kato D; Kaneko Y; Fukuda M; Izutsu H; Rokuda M
Mod Rheumatol; 2022 Jul; 32(4):708-717. PubMed ID: 34918131
[TBL] [Abstract][Full Text] [Related]
13. Exposure-response modeling of peficitinib efficacy in patients with rheumatoid arthritis.
Toyoshima J; Kaibara A; Shibata M; Kaneko Y; Izutsu H; Nishimura T
Pharmacol Res Perspect; 2021 May; 9(3):e00744. PubMed ID: 33929089
[TBL] [Abstract][Full Text] [Related]
14. Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.
Tanaka Y; Takeuchi T; Kato D; Kaneko Y; Fukuda M; Miyatake D
Mod Rheumatol; 2022 Jul; 32(4):696-707. PubMed ID: 34850095
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
[TBL] [Abstract][Full Text] [Related]
17. An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.
Cohen S; Pablos JL; Pavelka K; Müller GA; Matsumoto A; Kivitz A; Wang H; Krishnan E
Arthritis Res Ther; 2019 Mar; 21(1):84. PubMed ID: 30922373
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
19. Post hoc analysis of patients with rheumatoid arthritis under clinical remission in two Japanese Phase 3 trials of peficitinib treatment (RAJ3 and RAJ4).
Tanaka Y; Takeuchi T; Morita Y; Kato D; Kaneko Y; Terada W
Mod Rheumatol; 2024 Mar; 34(3):453-465. PubMed ID: 37319017
[TBL] [Abstract][Full Text] [Related]
20. Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Tanaka Y; Izutsu H
Expert Opin Pharmacother; 2020 Jun; 21(9):1015-1025. PubMed ID: 32345068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
